Infections
|
March 6, 2025

Mucormycosis Explained: Causes, Symptoms & Treatments

Written By
Medically Reviewed by
Updated On
April 2, 2025

Mucormycosis is a serious fungal infection that mainly affects people with weakened immune systems, including those recovering from COVID-19. During the pandemic, over 47,000 cases were reported in India alone, highlighting its rapid spread and severe impact. This infection can quickly invade the sinuses, brain, and lungs, making early recognition and treatment crucial.

This article explains mucormycosis, its causes, symptoms, and available treatments. Whether you’re looking for medical insights or are concerned about your health, this guide will help you understand and manage this serious condition.

[signup]

Understanding Mucormycosis

Mucormycosis is a serious and rare fungal infection caused by a group of molds known as Mucorales. These fungi are commonly found in the environment, particularly in soil, decaying organic matter, and the air. While they don’t typically harm healthy people, they can cause severe infections in individuals with weakened immune systems.

When inhaled or introduced through broken skin, these fungi can invade blood vessels, leading to tissue damage and, in severe cases, organ failure. Mucormycosis progresses rapidly, making early diagnosis and treatment crucial.

Overview of the Fungi Responsible (Mucorales)

Several species of fungi cause mucormycosis under the order Mucorales, including Rhizopus and Lichtheimia. These fungi thrive in damp, decaying environments and release spores that can be inhaled or enter the body through wounds. Once inside, they grow quickly, particularly in people with weakened immune systems, such as diabetes, cancer, or recent organ transplants.

Types of Mucormycosis

Mucormycosis can affect different parts of the body, leading to several types:

  • Rhino-orbital-cerebral Mucormycosis: This type affects the sinuses, eyes, and brain. It often starts in the nose or sinuses and can spread to the eyes and brain, causing facial pain, swelling, vision loss, and severe headaches.
  • Pulmonary Mucormycosis: This type affects the lungs, leading to cough, chest pain, fever, and shortness of breath. It is more common in people with cancer or organ transplants.
  • Cutaneous Mucormycosis: Occurs when the fungus enters through broken skin due to cuts, burns, or surgical wounds. It leads to red, swollen, and painful skin lesions that can turn black as tissue damage progresses.
  • Gastrointestinal Mucormycosis: This type affects the digestive system and is more common in premature infants or people with malnutrition. It causes abdominal pain, nausea, vomiting, and gastrointestinal bleeding.
  • Disseminated Mucormycosis: This severe form occurs when the infection spreads through the bloodstream, affecting multiple organs, including the brain, heart, and spleen. It can cause mental confusion, seizures, and even coma.

Epidemiology

Mucormycosis is rare but has been increasing worldwide, especially among people with weakened immune systems. The global incidence is estimated at 1.2 cases per million people annually, but outbreaks are more common in countries with high rates of diabetes and immunosuppression.

During the COVID-19 pandemic, India saw a significant rise in cases, with over 47,000 infections reported. This surge was linked to the widespread use of steroids to treat COVID-19, which weakened patients' immune systems, making them more vulnerable to fungal infections.

Populations most at risk include individuals with uncontrolled diabetes, cancer, organ transplants, or those on immunosuppressive medications. Additionally, malnutrition and trauma can increase the risk of developing mucormycosis.

Causes and Risk Factors

Mucormycosis is caused by a group of fungi known as Mucorales, which are commonly found in the environment. These fungi thrive in soil, decaying leaves, compost piles, and animal waste. They release microscopic spores into the air, which can be inhaled or enter the body through cuts or wounds.

The most common species responsible for mucormycosis include Rhizopus, Mucor, and Lichtheimia. While these fungi are harmless to most people, they can cause severe infections in individuals with weakened immune systems. Once inside the body, they invade blood vessels, leading to tissue damage and organ dysfunction.

Risk Factors

Certain conditions and circumstances increase the risk of developing mucormycosis, including:

  • Immunocompromised States: People with weakened immune systems are at the highest risk. This includes individuals with uncontrolled diabetes, cancer, or HIV/AIDS. High blood sugar levels, especially in diabetic ketoacidosis, create an environment that promotes fungal growth.
  • Trauma or Burns: Injuries that break the skin, such as cuts, burns, or surgical wounds, can allow fungal spores to enter the body, leading to cutaneous (skin) mucormycosis.
  • Use of Corticosteroids and Other Immunosuppressants: Medications like corticosteroids, often used to reduce inflammation, can weaken the immune system. During the COVID-19 pandemic, the use of steroids led to an increase in mucormycosis cases, particularly in patients with diabetes.

Environmental Exposure

Mucorales fungi are present in everyday environments, including:

  • Common Sources of Fungal Spores: Soil, decaying organic matter, compost piles, and dust are all common sources of Mucorales spores. Activities like gardening, farming, or construction work can increase exposure.
  • Occupational Hazards: Certain jobs carry a higher risk of exposure, including agricultural work, construction, and jobs involving soil or decaying plant material. People working in these fields should take precautions, especially if they have underlying health conditions.

Symptoms and Diagnosis

Mucormycosis symptoms vary depending on the type of infection and the area of the body affected. Early recognition is crucial for effective treatment.

  • Rhino-orbital-cerebral Mucormycosis: This type affects the sinuses, eyes, and brain. Early symptoms include facial pain, nasal congestion, and headaches. As it progresses, symptoms can worsen, including swelling around the eyes, vision loss, and black lesions on the nasal bridge or upper mouth.
  • Pulmonary Mucormycosis: When the lungs are affected, symptoms may include fever, cough, chest pain, and shortness of breath. These symptoms are often mistaken for pneumonia or tuberculosis.
  • Cutaneous Mucormycosis: This type begins as red, swollen skin lesions, which can quickly turn black due to tissue death. It is commonly seen after cuts, burns, or surgery.
  • Gastrointestinal Mucormycosis: Symptoms include abdominal pain, nausea, vomiting, and gastrointestinal bleeding. It is more common in young children or those with malnutrition.
  • Disseminated Mucormycosis: This severe form spreads through the bloodstream, affecting multiple organs, including the brain. Symptoms can include mental confusion, seizures, and even coma.

Diagnostic Procedures

Early and accurate diagnosis is essential to manage mucormycosis effectively. The following procedures are commonly used:

  • Clinical Examination: A doctor will assess symptoms, medical history, and potential exposure risks. For rhino-orbital-cerebral mucormycosis, they may look for black lesions in the nasal or oral cavity.
  • Imaging Techniques: CT and MRI scans help visualize the extent of the infection. In rhino-orbital-cerebral cases, imaging can reveal sinus inflammation or brain involvement. For pulmonary mucormycosis, CT scans show lung nodules or cavities.
  • Laboratory Tests: Tissue biopsies are often taken to confirm the presence of fungal hyphae. Cultures help identify the specific species of Mucorales. Polymerase chain reaction (PCR) tests can detect fungal DNA, speeding up the diagnostic process.

Differential Diagnosis

Due to overlapping symptoms, mucormycosis can be easily confused with other fungal infections, such as aspergillosis or candidiasis. However, there are key differences:

  • Aspergillosis: This fungal infection also affects the lungs and sinuses but typically progresses more slowly and is less invasive.
  • Candidiasis: Usually involves mucous membranes or the bloodstream, but does not cause black necrotic lesions like mucormycosis.

Treatment and Management

Treating mucormycosis requires prompt and aggressive antifungal therapy. Early intervention is crucial to prevent the infection from spreading.

  • First-line Medications: The most commonly used antifungal for mucormycosis is Amphotericin B, specifically the liposomal form. It is administered intravenously and works by targeting the fungal cell membrane. Treatment usually continues for several weeks, depending on the severity of the infection.
  • Alternative Antifungals: If patients cannot tolerate Amphotericin B or need additional therapy, other antifungals like Posaconazole and Isavuconazole are used. These medications are available in oral and intravenous forms, making long-term management easier.

Surgical Interventions

Medication alone often isn’t enough to treat mucormycosis. Surgery is usually needed to remove infected and dead tissue, which helps stop the fungus from spreading to nearby areas.

Surgery is especially important when there is significant tissue damage, as seen in rhino-orbital-cerebral or cutaneous mucormycosis.  

The type of surgery depends on where the infection is located:

  • Debridement: Involves removing dead and infected tissue, commonly used for skin infections.
  • Sinus Surgery: Clears infected tissue in the sinuses, preventing the spread to the eyes or brain.
  • Lung Resection: This procedure involves removing the affected part of the lung, which may be needed in severe lung infections.

Supportive Care

Managing mucormycosis requires more than antifungal drugs and surgery. Supportive care is essential for better patient outcomes.

Controlling underlying health conditions is essential, as mucormycosis mainly affects those with weakened immune systems. 

  • For people with diabetes, keeping blood sugar levels in check is vital, especially in cases of diabetic ketoacidosis. 
  • Adjusting immunosuppressive medications, like corticosteroids, can also help the immune system fight the infection more effectively.

Early intervention is critical because mucormycosis spreads quickly. Rapid diagnosis, prompt antifungal treatment, and timely surgery can greatly improve survival rates. Delays can cause severe tissue damage and complications.

Emerging Treatments

Research into new therapies for mucormycosis is ongoing, offering hope for more effective and less toxic treatment options.

  • Latest Research: Studies are exploring the use of combination antifungal therapies and new drug formulations that target fungi more precisely. Researchers are also investigating immunotherapy approaches to enhance the body’s immune response against Mucorales fungi.
  • Potential Future Therapies: Experimental drugs like VT-1598 are showing promise in preclinical trials. These new antifungals aim to be more effective while minimizing side effects. Additionally, advances in genetic research could lead to targeted therapies that disrupt the fungus's ability to invade human tissues.

Prevention and Awareness

To prevent mucormycosis, it’s essential to manage underlying health conditions, especially diabetes. 

  • Keeping blood sugar levels in check reduces the risk of infection. 
  • If you have a weakened immune system, avoid exposure to dust, soil, and decaying organic matter. 
  • When exposure is necessary, wear protective masks. 
  • Keep cuts and burns clean and covered until fully healed. 
  • Use corticosteroids only under medical supervision to avoid weakening your immune system. 

Knowing the early symptoms can help you seek timely medical attention. Education and awareness are key, so stay informed and spread knowledge within your community.

Living with Mucormycosis

Living with mucormycosis requires strict adherence to treatment plans, including taking medications as prescribed and attending follow-up appointments. Managing underlying conditions, like diabetes, helps prevent recurrence. Emotional support is also important; consider counseling or joining support groups to cope with anxiety or depression.

Maintaining a healthy lifestyle supports recovery. Eat a balanced diet, stay hydrated, rest well, and exercise as advised by your doctor. Stay alert for any new symptoms and report them immediately. With proper care and support, it’s possible to live well with mucormycosis.

[signup]

Key Takeaways

  • Mucormycosis is a rare but severe fungal infection that primarily affects people with weakened immune systems, such as those with diabetes, cancer, or recent organ transplants.
  • The infection is caused by Mucorales fungi, commonly found in soil, decaying organic matter, and air. These fungi can enter the body through inhalation or open wounds and lead to rapid tissue damage.
  • Symptoms vary by type but may include facial pain, swelling, vision loss (rhino-orbital-cerebral), cough and shortness of breath (pulmonary), and black necrotic skin lesions (cutaneous), making early diagnosis critical.
  • Treatment requires urgent antifungal therapy, primarily with Amphotericin B. When necessary, infected tissue must be surgically removed. Underlying health conditions must also be managed to improve outcomes.
  • Prevention focuses on controlling blood sugar levels, avoiding exposure to soil and dust for high-risk individuals, maintaining proper wound care, and limiting the use of immunosuppressive medications when possible.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!

A Frieddmann, J. (2024, November 7). How Functional Medicine Practitioners View Inflammation. Rupa Health. https://www.rupahealth.com/post/how-functional-medicine-practitioners-view-inflammation-2

Abdullah Alqarihi, Kontoyiannis, D. P., & Ibrahim, A. S. (2023). Mucormycosis in 2023: an update on pathogenesis and management. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1254919

Agrawal, R., Yeldandi, A., Savas, H., Parekh, N. D., Lombardi, P. J., & Hart, E. M. (2020). Pulmonary Mucormycosis: Risk Factors, Radiologic Findings, and Pathologic Correlation. RadioGraphics, 40(3), 656–666. https://doi.org/10.1148/rg.2020190156

AK, A. K., & Gupta, V. (2023). Rhino-Orbital Cerebral Mucormycosis. StatPearls. https://pubmed.ncbi.nlm.nih.gov/32491361/

Bhanuprasad, K., Manesh, A., Devasagayam, E., Varghese, L., Cherian, L. M., Kurien, R., Karthik, R., Deodhar, D., Vanjare, H., Peter, J., Michael, J. S., Thomas, M., Samuel, P., & Varghese, G. M. (2021). Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. International Journal of Infectious Diseases, 111, 267–270. https://doi.org/10.1016/j.ijid.2021.08.037

Biradar, S. (2016). Mucormycosis in a Diabetic Ketoacidosis Patient: A Case Report. JOURNAL of CLINICAL and DIAGNOSTIC RESEARCH. https://doi.org/10.7860/jcdr/2016/16241.7734

Blake, K. (2023, December 15). The Power of Functional Foods in Cancer Prevention. Rupa Health. https://www.rupahealth.com/post/the-power-of-functional-foods-in-cancer-prevention

Bowers, J. R., Monroy-Nieto, J., Gade, L., Travis, J., Refojo, N., Abrantes, R., Santander, J., French, C., Dignani, M. C., Hevia, A. I., Roe, C. C., Lemmer, D., Lockhart, S. R., Chiller, T., Litvintseva, A. P., Clara, L., & Engelthaler, D. M. (n.d.). Rhizopus microsporus Infections Associated with Surgical Procedures, Argentina, 2006–2014 - Volume 26, Number 5—May 2020 - Emerging Infectious Diseases journal - CDC. Wwwnc.cdc.gov. https://doi.org/10.3201/eid2605.191045

Brunet, K., & Rammaert, B. (2020). Mucormycosis treatment: Recommendations, latest advances, and perspectives. Journal de Mycologie Médicale, 101007. https://doi.org/10.1016/j.mycmed.2020.101007

Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., Mellinghoff, S. C., Mer, M., Pana, Z. D., Seidel, D., Sheppard, D. C., Wahba, R., Akova, M., Alanio, A., Al-Hatmi, A. M. S., & Arikan-Akdagli, S. (2019). Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. The Lancet Infectious Diseases, 19(12), e405–e421. https://doi.org/10.1016/s1473-3099(19)30312-3

de Roquetaillade, C., Paktoris, H., Hamon, M., & Bruneel, F. (2019). Disseminated mucormycosis. Intensive Care Medicine, 45(10), 1480–1481. https://doi.org/10.1007/s00134-019-05625-x

EJ Kyriopoulos, Kyriakopoulos, A., A Karonidis, A Gravvanis, I Gamatsi, C Tsironis, & D Tsoutsos. (2015). Burn injuries and soft tissue traumas complicated by mucormycosis infection: a report of six cases and review of the literature. Annals of Burns and Fire Disasters, 28(4), 280. https://pmc.ncbi.nlm.nih.gov/articles/PMC5068897/

Fosses Vuong, M., & Waymack, J. R. (2020). Aspergillosis. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482241/

Frédéric Lamoth. (2023). Novel Approaches in the Management of Mucormycosis. Current Fungal Infection Reports, 17(2), 98–107. https://doi.org/10.1007/s12281-023-00463-3

Ghazi, B. K., Rackimuthu, S., Wara, U. U., Mohan, A., Khawaja, U. A., Ahmad, S., Ahmad, S., Hasan, M. M., dos Santos Costa, A. C., Ahmad, S., & Essar, M. Y. (2021). Rampant Increase in Cases of Mucormycosis in India and Pakistan: A Serious Cause for Concern during the Ongoing COVID-19 Pandemic. The American Journal of Tropical Medicine and Hygiene, 105(5), 1144–1147. https://doi.org/10.4269/ajtmh.21-0608

Gunathilaka, S. S., Keragala, R. K., Gunathilaka, K. M., Wickramage, S., Bandara, S. R., Senevirathne, I. S., & Jayaweera, A. S. (2025). Use of isavuconazole in mucormycosis: a systematic review. BMC Infectious Diseases, 25(1), 25. https://doi.org/10.1186/s12879-025-10439-y

Gupta, M. K., Kumar, N., Dhameja, N., Sharma, A., & Tilak, R. (2022). Laboratory diagnosis of mucormycosis: Present perspective. Journal of Family Medicine and Primary Care, 11(5), 1664–1671. https://doi.org/10.4103/jfmpc.jfmpc_1479_21

Hammer, M. M., Madan, R., & Hatabu, H. (2018). Pulmonary Mucormycosis: Radiologic Features at Presentation and Over Time. American Journal of Roentgenology, 210(4), 742–747. https://doi.org/10.2214/ajr.17.18792

Joshi, A. R., Mridula Manohar Muthe, Patankar, S. H., Ashish Athawale, & Yash Achhapalia. (2021). CT and MRI Findings of Invasive Mucormycosis in the Setting of COVID-19: Experience From a Single Center in India. American Journal of Roentgenology, 217(6), 1431–1432. https://doi.org/10.2214/ajr.21.26205

Khanna, M., Challa, S., Kabeil, A. S., Inyang, B., Gondal, F. J., Abah, G. A., Dhandapani, M. M., Manne, M., & Mohammed, L. (2021). Risk of Mucormycosis in Diabetes Mellitus: A Systematic Review. Cureus, 13(10). https://doi.org/10.7759/cureus.18827

Kiruthiga, K. G., Kulkarni, A., Joshi, A., Pradhan, A., & Naik, S. (2024). Diagnosis of Mucormycosis Using Frozen Section, Histopathology, Culture, and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Techniques: A Comparative Study. Cureus, 16(3), e56160. https://doi.org/10.7759/cureus.56160

Maholy, N. (2023, May 10). A Functional Medicine Immune Support Protocol. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-immune-support-protocol

Mazzai, L., Anglani, M., Giraudo, C., Martucci, M., Cester, G., & Causin, F. (2021). Imaging features of rhinocerebral mucormycosis: from onset to vascular complications. Acta Radiologica, 63(2), 232–244. https://doi.org/10.1177/0284185120988828

Meena, D. S., Kumar, D., & Bohra, G. K. (2023). Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review. Journal de Mycologie Medicale, 33(1), 101332. https://doi.org/10.1016/j.mycmed.2022.101332

Mohsen, A. Y., Mohammad, J. G., & Hussein Al-janabi, M. (2022). Mucormycosis (black fungus) infection and misuse of corticosteroids in COVID 19 patients in Syria. Annals of Medicine and Surgery, 75, 103463. https://doi.org/10.1016/j.amsu.2022.103463

Muthu, V., Rudramurthy, S. M., Chakrabarti, A., & Agarwal, R. (2021). Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World. Mycopathologia. https://doi.org/10.1007/s11046-021-00584-8

Petrikkos, G., Skiada, A., Lortholary, O., Roilides, E., Walsh, T. J., & Kontoyiannis, D. P. (2012). Epidemiology and Clinical Manifestations of Mucormycosis. Clinical Infectious Diseases, 54(suppl_1), S23–S34. https://doi.org/10.1093/cid/cir866

R, A. N., & Rafiq, N. B. (2023, May 29). Candidiasis. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK560624/

Reid, G., Lynch, J. P., Fishbein, M. C., & Clark, N. M. (2020). Mucormycosis. Seminars in Respiratory and Critical Care Medicine, 41(01), 099-114. https://doi.org/10.1055/s-0039-3401992

Richardson, M. D., & Rautemaa-Richardson, R. (2019). Biotic Environments Supporting the Persistence of Clinically Relevant Mucormycetes. Journal of Fungi, 6(1), 4. https://doi.org/10.3390/jof6010004

Sachdeva, A., Targhotra, M., Chauhan, M. K., & Chopra, M. (2024). Role of Amphotericin B in the Treatment of Mucormycosis. Current Pharmaceutical Design, 30(1), 1–9. https://doi.org/10.2174/0113816128272443231221101415

Sagar Regmi, & Premlal Mahato. (2023). Mucormycosis: Issues, Pathophysiology, Diagnosis and Treatment. Journal of Karnali Academy of Health Sciences, 6(1). https://doi.org/10.61814/jkahs.v6i1.521

Schwartze, V. U., Hoffmann, K., Nyilasi, I., Papp, T., Vágvölgyi, C., de Hoog, S., Voigt, K., & Jacobsen, I. D. (2012). Lichtheimia Species Exhibit Differences in Virulence Potential. PLoS ONE, 7(7), e40908. https://doi.org/10.1371/journal.pone.0040908

Seo, H., Kim, J. Y., Son, H.-J., Jung, J., Kim, M. J., Chong, Y. P., Lee, S.-O., Choi, S.-H., Kim, Y. S., & Kim, S.-H. (2021). Diagnostic performance of real-time polymerase chain reaction assay on blood for invasive aspergillosis and mucormycosis. Mycoses, 64(12), 1554–1562. https://doi.org/10.1111/myc.13319

Skiada, A., Pavleas, I., & Drogari-Apiranthitou, M. (2020). Epidemiology and Diagnosis of Mucormycosis: An Update. Journal of Fungi, 6(4), 265. https://doi.org/10.3390/jof6040265

Skiada, A., & Petrikkos, G. (2013). Cutaneous mucormycosis. Skinmed, 11(3), 155–159; quiz 159-60. https://pubmed.ncbi.nlm.nih.gov/23930354/

Smith, C., & Lee, S. C. (2022). Current treatments against mucormycosis and future directions. PLOS Pathogens, 18(10), e1010858. https://doi.org/10.1371/journal.ppat.1010858

Sweetnich, J. (2023, April 25). Complementary and Integrative Medicine Approaches to Type 2 Diabetes Management. Rupa Health. https://www.rupahealth.com/post/complementary-and-integrative-medicine-approaches-to-type-2-diabetes-management

Walther, G., Wagner, L., & Kurzai, O. (2020). Outbreaks of Mucorales and the Species Involved. Mycopathologia, 185(5), 765–781. https://doi.org/10.1007/s11046-019-00403-1

Waterer, G. (2021). Advances in anti-fungal therapies. Mycopathologia. https://doi.org/10.1007/s11046-021-00560-2

Wilson, E. (2024, December 19). Low-Grade Fever: Causes, Symptoms, and Management. Rupa Health. https://www.rupahealth.com/post/low-grade-fever-causes-symptoms-and-management

Yazan Addasi, Nguyen, A. H., Sabri, A., Ahmad, F., Rajani Rangray, & Manasa Velagapudi. (2023). Gastrointestinal Mucormycosis: A Clinical Review. Gastroenterology Research, 16(5), 249–253. https://doi.org/10.14740/gr1662

Zahoor, B., Piercey, J., Wall, D., & Tetsworth, K. (2016). A surgical approach in the management of mucormycosis in a trauma patient. Annals of the Royal College of Surgeons of England, 98(8), e173–e177. https://doi.org/10.1308/rcsann.2016.0221

Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Infections
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.